Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Porto – page 40

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Porto at a glance
498
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

498 trials in Porto

Open in trial search

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
  • Sponsor:Bial R&D Investments S.A.

Obesity+1

Not recruiting

Study on the Effects of Semaglutide for Weight Management in Children and Adolescents with Obesity or Overweight

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Not recruiting

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Dimerix Bioscience Pty Limited

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Small cell lung cancer recurrent

Not recruiting

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of Tenecteplase for Patients with Acute Ischemic Stroke and Incomplete Reperfusion After Mechanical Thrombectomy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Insel Gruppe AG

Dry age-related macular degeneration

Not recruiting

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Thermal burn

Not recruiting

Study on the Effects of High-Dose Vitamin C in Patients with Severe Burns

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Queen's University

Myelodysplastic syndrome

Not recruiting

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

  • Vision disorders
  • Genetic disorders
  • Treatment efficacy studies
02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

  • Blood cancers
  • Solid tumors
  • Immunotherapy
03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

  • Inflammatory skin conditions
  • Autoimmune disorders
  • Novel biologics
04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

  • Heart conditions
  • Metabolic diseases
  • Weight management
05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

  • Neurological disorders
  • Rare diseases
  • Pain management
Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.